Evidence map›Paper›PMID 38416176›Full record

ArticleCardiovascular and interventional radiology2024

Prostatic Artery Embolization in Patients with Advanced Prostate Cancer: A Prospective Single Center Pilot Study.

Orlando Burkhardt, Dominik Abt, Lukas Hechelhammer, Olaf Kim, Aurelius Omlin, Hans-Peter Schmid, Daniel Engeler, Valentin Zumstein, Gautier Müllhaupt

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03457805 (Prostatic Artery Embolization), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03457805 naunknown statusnot on this map

Prostatic Artery Embolization (PAE) in Patients With Advanced Prostate Cancer: A Pilot Study.

TypeinterventionalSponsorDominik AbtRan2018 to 2021Enrolled20ConditionsProstate Cancer, Bladder Outlet ObstructionArmsProstatic Artery Embolization
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. What Role Does PAE Play in the Management of Prostate Cancer?Cardiovascular and interventional radiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Orlando BurkhardtDepartment of Urology, School of Medicine, University of St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland. orlando.burkhardt@kssg.ch.ORCID http://orcid.org/0000-0003-1376-0474
Dominik AbtDepartment of Urology, School of Medicine, University of St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
Lukas HechelhammerDepartment of Radiology and Nuclear Medicine, St. Gallen Cantonal Hospital, St. Gallen, Switzerland.
Olaf KimDepartment of Radiology and Nuclear Medicine, St. Gallen Cantonal Hospital, St. Gallen, Switzerland.
Aurelius OmlinOnkozentrum Zürich und Uroonkologisches Zentrum, Hirslanden Zürich, Seestrasse 259, 8038, Zurich, Switzerland.
Hans-Peter SchmidDepartment of Urology, School of Medicine, University of St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
Daniel EngelerDepartment of Urology, School of Medicine, University of St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
Valentin ZumsteinDepartment of Urology, School of Medicine, University of St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
Gautier MüllhauptDepartment of Urology, School of Medicine, University of St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
University of St.Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess efficacy and safety of prostatic artery embolization (PAE) in patients with advanced prostate cancer (PCa). MATERIALS AND

methodsIn this prospective single-center, single-arm, pilot study, 9 men with advanced PCa underwent PAE. PAE was performed with the use of 250-400 µm Embozene microspheres (Boston Scientific, Natick, Massachusetts, USA). International Prostate Symptoms Score (IPSS), urinary peak flow (Qmax) and post-void residual urine volume (PVR) was assessed at 12 weeks and up to 12 months. Changes in total prostate volume (TPV) and tumor responses by PSA, changes in tumor volume and evaluation of tumor regression by multiparametric magnetic resonance imaging were assessed at 12 weeks after PAE.

resultsIPSS reduction in median 6 points (0-19) and a significant decrease in PVR from median 70 (20-600) mL to 10 (0-280) mL could be achieved within 12 weeks after PAE. Median TPV and tumor volumes (TV) increased slightly from 19.7 (6.4-110.8) mL to 23.4 (2.4-66.3) mL and 6.4 (4.6-18.3) mL to 8.1 (2.4-25.6) mL at a median of 12 weeks after the procedure. Significant tumor necrosis (≥ 50%) was found in one patient. Eight patients showed > 50% of viable tumor on post-PAE MRI according to MRI. Only one Clavien-Dindo Grade 1 adverse event related to PAE occurred.

conclusionsPAE with the use of 250-400 µm microspheres is feasible, safe and effective in some patients with advanced PCa regarding functional outcomes. A cytoreductive effect might be achieved in individual patients but must be further assessed. TRIALS REGISTRATION: NCT03457805.

Indexed as

Embolization, TherapeuticProstateProstatic NeoplasmsAcrylic ResinsAgedAged, 80 and overGelatinHumansMagnetic Resonance ImagingMaleMicrospheresMiddle AgedPilot ProjectsProspective StudiesTreatment OutcomeAcrylic ResinsGelatintrisacryl gelatin microspheresAdvanced prostate cancerCytoreductionEmbolizationPilot studyProstateProstatic artery embolization

Identifiers

PMID38416176
OpenAlexW4392242270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.